These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16250647)

  • 1. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
    Minetti P; Tinti MO; Carminati P; Castorina M; Di Cesare MA; Di Serio S; Gallo G; Ghirardi O; Giorgi F; Giorgi L; Piersanti G; Bartoccini F; Tarzia G
    J Med Chem; 2005 Nov; 48(22):6887-96. PubMed ID: 16250647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535.
    Galluzzo M; Pintor A; Pèzzola A; Grieco R; Borsini F; Popoli P
    Eur J Pharmacol; 2008 Jan; 579(1-3):149-52. PubMed ID: 18036583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.
    Piersanti G; Bartoccini F; Lucarini S; Cabri W; Stasi MA; Riccioni T; Borsini F; Tarzia G; Minetti P
    J Med Chem; 2013 Jul; 56(13):5456-63. PubMed ID: 23789814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
    Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Preti D; Tabrizi MA; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Merighi S; Varani K; Borea PA
    J Med Chem; 2005 Jul; 48(14):4697-701. PubMed ID: 16000006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
    Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Preti D; Zaid AN; Saponaro G; Tabrizi MA; Baraldi S; Romagnoli R; Moorman AR; Varani K; Cosconati S; Di Maro S; Marinelli L; Novellino E; Borea PA
    J Med Chem; 2011 Jul; 54(14):5205-20. PubMed ID: 21675777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists.
    Pastorin G; Bolcato C; Cacciari B; Kachler S; Klotz KN; Montopoli C; Moro S; Spalluto G
    Farmaco; 2005 Apr; 60(4):299-306. PubMed ID: 15848204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity.
    Bevan N; Butchers PR; Cousins R; Coates J; Edgar EV; Morrison V; Sheehan MJ; Reeves J; Wilson DJ
    Eur J Pharmacol; 2007 Jun; 564(1-3):219-25. PubMed ID: 17382926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
    Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
    ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological and modeling studies of 1,3-di-n-propyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as adenosine receptor antagonists.
    Pastorin G; Bolcato C; Cacciari B; Kachler S; Klotz KN; Montopoli C; Moro S; Spalluto G
    Farmaco; 2005 Aug; 60(8):643-51. PubMed ID: 15961085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones.
    Drabczyńska A; Yuzlenko O; Köse M; Paskaleva M; Schiedel AC; Karolak-Wojciechowska J; Handzlik J; Karcz T; Kuder K; Müller CE; Kieć-Kononowicz K
    Eur J Med Chem; 2011 Sep; 46(9):3590-607. PubMed ID: 21664729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
    J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
    Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
    J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists.
    Kiselgof E; Tulshian DB; Arik L; Zhang H; Fawzi A
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2119-22. PubMed ID: 15808481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands.
    Lambertucci C; Antonini I; Buccioni M; Dal Ben D; Kachare DD; Volpini R; Klotz KN; Cristalli G
    Bioorg Med Chem; 2009 Apr; 17(7):2812-22. PubMed ID: 19282184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
    Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
    J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-affinity relationship investigations of 5-heteroaryl-substituted analogues of the antipsychotic sertindole. A new class of highly selective alpha(1) adrenoceptor antagonists.
    Balle T; Perregaard J; Ramirez MT; Larsen AK; Søby KK; Liljefors T; Andersen K
    J Med Chem; 2003 Jan; 46(2):265-83. PubMed ID: 12519065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.